Committee Action
The Committee on Ways and Means marked up H.R. 842, the
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection
Screening Coverage Act, on September 17, 2025, and favorably
reported the bill, as amended, to the House of Representatives
(with a quorum being present).
D. Designated Hearing
Pursuant to clause 3(c)(6) of rule XIII, the following
hearing was used to develop and consider H.R. 842:
``Modernizing American Health Care: Creating Healthy
Options and Better Incentives,'' on February 11, 2025.
II. EXPLANATION OF THE BILL
A. Reasons for Change
The Committee on Ways and Means' reason for change is to
provide Medicare coverage of multi-cancer early detection
screening tests.
B. Explanation of Provisions
Section 1. Short Title
The short title is ``Nancy Gardner Sewell Medicare Multi-
Cancer Early Detection Screening Coverage Act''.
Section 2. Medicare Coverage of Multi-Cancer Early Detection Screening
Tests
This provision provides temporary Medicare coverage of
multi-cancer early detection screening tests to seniors aged 65
once a year and maintains that coverage through their lifetime
in the program. In the case the United States Preventive
Services Task Force issues an ``A'' or ``B'' rating, then the
temporary coverage is removed and Medicare undertakes its
normal coverage process.
C. Effective Date
The bill, as amended, would become effective January 1,
2029.
III. VOTES OF THE COMMITTEE
In compliance with the Rules of the House of
Representatives, the following statement is made concerning the
vote of the Committee on Ways and Means during the markup
consideration of H.R. 842, the ``Nancy Gardner Sewell Medicare
Multi-Cancer Early Detection Screening Coverage Act,'' on
September 17, 2025.
H.R. 842 was ordered favorably reported to the House of
Representatives as amended by a roll call vote of 43 yeas to 0
nays (with a quorum being present). The vote was as follows:
----------------------------------------------------------------------------------------------------------------
Representative Yea Nay Present Representative Yea Nay Present
----------------------------------------------------------------------------------------------------------------
Mr. Smith (MO)..................... X ...... ......... Mr. Neal............. X ...... .........
Mr. Buchanan....................... X ...... ......... Mr. Doggett.......... X ...... .........
Mr. Smith (NE)..................... X ...... ......... Mr. Thompson......... X ...... .........
Mr. Kelly.......................... X ...... ......... Mr. Larson........... X ...... .........
Mr. Schweikert..................... X ...... ......... Mr. Davis............ X ...... .........
Mr. LaHood......................... X ...... ......... Ms. Sanchez.......... ...... ...... .........
Mr. Arrington...................... X ...... ......... Ms. Sewell........... X ...... .........
Mr. Estes.......................... X ...... ......... Ms. DelBene.......... X ...... .........
Mr. Smucker........................ X ...... ......... Ms. Chu.............. X ...... .........
Mr. Hern........................... X ...... ......... Ms. Moore............ X ...... .........
Mrs. Miller........................ X ...... ......... Mr. Boyle............ X ...... .........
Dr. Murphy......................... X ...... ......... Mr. Beyer............ X ...... .........
Mr. Kustoff........................ X ...... ......... Mr. Evans............ X ...... .........
Mr. Fitzpatrick.................... X ...... ......... Mr. Schneider........ X ...... .........
Mr. Steube......................... X ...... ......... Mr. Panetta.......... X ...... .........
Ms. Tenney......................... X ...... ......... Mr. Gomez............ X ...... .........
Mrs. Fischbach..................... X ...... ......... Mr. Horsford......... ...... ...... .........
Mr. Moore.......................... X ...... ......... Ms. Plaskett......... X ...... .........
Ms. Van Duyne...................... X ...... ......... Mr. Suozzi........... X ...... .........
Mr. Feenstra....................... X ...... .........
Ms. Malliotakis.................... X ...... .........
Mr. Carey.......................... X ...... .........
Mr. Yakym.......................... X ...... .........
Mr. Miller......................... X ...... .........
Mr. Bean........................... X ...... .........
Mr. Moran.......................... X ...... .........
----------------------------------------------------------------------------------------------------------------
IV. BUDGET EFFECTS OF THE BILL
A. Committee Estimate of Budgetary Effects
With respect to clause 3(d) of rule XIII of the Rules of
the House of Representatives, a cost estimate provided by the
Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not made available to the
Committee in time for the filing of this report.
B. Statement Regarding New Budget Authority and
Tax Expenditures Budget Authority
In compliance with clause 3(c)(2) of rule XIII of the Rules
of the House of Representatives, the Committee states that the
bill involved no new or increased budget authority. The
Committee states further that the bill involves no new or
increased tax expenditures.
C. Cost Estimate Prepared by the
Congressional Budget Office
With respect to the requirements of clause 3(c)(2) of rule
XIII of the Rules of the House of Representatives and section
308(a) of the Congressional Budget Act of 1974 and with respect
to requirements of clause (3)(c)(3) of rule XIII of the Rules
of the House of Representatives and section 402 of the
Congressional Budget Act of 1974, the Committee has requested
but not received a cost estimate for this bill from the
Director of Congressional Budget Office. The Chairman of the
Committee shall cause such estimate and statement to be printed
in the Congressional Record upon its receipt by the Committee.
V. OTHER MATTERS TO BE DISCUSSED UNDER
THE RULES OF THE HOUSE
A. Committee Oversight Findings and Recommendations
With respect to clause 3(c)(1) of rule XIII of the Rules of
the House of Representatives, the Committee made findings and
recommendations that are reflected in this report.
B. Statement of General Performance Goals and Objectives
With respect to clause 3(c)(4) of rule XIII of the Rules of
the House of Representatives, the Committee advises that the
bill does not authorize funding, so no statement of general
performance goals and objectives is required.
C. Information Relating to Unfunded Mandates
This information is provided in accordance with section 423
of the Unfunded Mandates Reform Act of 1995 (Pub. L. No. 104-
4).
The Committee has determined that the bill does not contain
Federal mandates on the private sector. The Committee has
determined that the bill does not impose a Federal
intergovernmental mandate on State, local, or tribal
governments.
D. Congressional Earmarks, Limited Tax Benefits,
and Limited Tariff Benefits
With respect to clause 9 of rule XXI of the Rules of the
House of Representatives, the Committee has carefully reviewed
the provisions of the bill, and states that the provisions of
the bill do not contain any congressional earmarks, limited tax
benefits, or limited tariff benefits within the meaning of the
rule.
E. Duplication of Federal Programs
In compliance with clause 3(c)(5) of rule XIII of the Rules
of the House of Representatives, the Committee states that no
provision of the bill establishes or reauthorizes: (1) a
program of the Federal Government known to be duplicative of
another Federal program; (2) a program included in any report
from the Government Accountability Office to Congress pursuant
to section 21 of Public Law 111-139; or (3) a program related
to a program identified in the most recent Catalog of Federal
Domestic Assistance, published pursuant to the Federal Program
Information Act (Pub. L. No. 95-220, as amended by Pub. L. No.
98-169).
VI. CHANGES IN EXISTING LAW MADE BY THE BILL,
AS REPORTED
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
SOCIAL SECURITY ACT
* * * * * * *
TITLE XVIII--HEALTH INSURANCE FOR THE AGED AND
DISABLED
* * * * * * *
Part B--Supplementary Medical Insurance Benefits for the
Aged and Disabled
* * * * * * *
PAYMENT OF BENEFITS
Sec. 1833. (a) Except as provided in section 1876, and
subject to the succeeding provisions of this section, there
shall be paid from the Federal Supplementary Medical Insurance
Trust Fund, in the case of each individual who is covered under
the insurance program established by this part and incurs
expenses for services with respect to which benefits are
payable under this part, amounts equal to--(1) in the case of
services described in section 1832(a)(1)--80 percent of the
reasonable charges for the services; except that (A) an
organization which provides medical and other health services
(or arranges for their availability) on a prepayment basis (and
either is sponsored by a union or employer, or does not
provide, or arrange for the provision of, any inpatient
hospital services) may elect to be paid 80 percent of the
reasonable cost of services for which payment may be made under
this part on behalf of individuals enrolled in such
organization in lieu of 80 percent of the reasonable charges
for such services if the organization undertakes to charge such
individuals no more than 20 percent of such reasonable cost
plus any amounts payable by them as a result of subsection (b),
(B) with respect to items and services described in section
1861(s)(10)(A), the amounts paid shall be 100 percent of the
reasonable charges for such items and services, (C) with
respect to expenses incurred for those physicians' services for
which payment may be made under this part that are described in
section 1862(a)(4), the amounts paid shall be subject to such
limitations as may be prescribed by regulations, (D) with
respect to clinical diagnostic laboratory tests for which
payment is made under this part (i)(I) on the basis of a fee
schedule under subsection (h)(1) (for tests furnished before
January 1, 2017) or [section 1834(d)(1)] subsection (d)(1) or
(aa) of section 1834, the amount paid shall be equal to 80
percent (or 100 percent, in the case of such tests for which
payment is made on an assignment-related basis) of the lesser
of the amount determined under such fee schedule, the
limitation amount for that test determined under subsection
(h)(4)(B), or the amount of the charges billed for the tests,
or (II) under section 1834A (for tests furnished on or after
January1, 2017), the amount paid shall be equal to 80
percent(or 100 percent, in the case of such tests for which
payment is made on an assignment-related basis) of the lesser
of the amount determined under such section or the amount of
the charges billed for the tests, or (ii) for tests furnished
before January 1, 2017,on the basis of a negotiated rate
established under subsection (h)(6), the amount paid shall be
equal to 100 percent of such negotiated rate,,(E) with respect
to services furnished to individuals who have been determined
to have end stage renal disease, the amounts paid shall be
determined subject to the provisions of section 1881,(F) with
respect to clinical social worker services under section
1861(s)(2)(N), the amounts paid shall be 80 percent of the
lesser of (i) the actual charge for the services or (ii) 75
percent of the amount determined for payment of a psychologist
under clause (L),
(G) with respect to facility services
furnished in connection with a surgical
procedure specified pursuant to subsection
(i)(1)(A) and furnished to an individual in an
ambulatory surgical center described in such
subsection, for services furnished beginning
with the implementation date of a revised
payment system for such services in such
facilities specified in subsection (i)(2)(D),
the amounts paid, subject to subsection (i)(9),
shall be 80 percent of the lesser of the actual
charge for the services or the amount
determined by the Secretary under such revised
payment system,
(H) with respect to services of a certified
registered nurse anesthetist under section 1861(s)(11),
the amounts paid shall be 80 percent of the least of
the actual charge, the prevailing charge that would be
recognized (or, for services furnished on or after
January 1, 1992, the fee schedule amount provided under
section 1848) if the services had been performed by an
anesthesiologist, or the fee schedule for such services
established by the Secretary in accordance with
subsection (l), (I) with respect to covered items
(described in section 1834(a)(13)), the amounts paid
shall be the amounts described in section 1834(a)(1),
and(J) with respect to expenses incurred for
radiologist services (as defined in section
1834(b)(6)), subject to section 1848, the amounts paid
shall be 80 percent of the lesser of the actual charge
for the services or the amount provided under the fee
schedule established under section 1834(b), (K) with
respect to certified nurse-midwife services under
section 1861(s)(2)(L), the amounts paid shall be 80
percent of the lesser of the actual charge for the
services or the amount determined by a fee schedule
established by the Secretary for the purposes of this
subparagraph (but in no event shall such fee schedule
exceed 65 percent of the prevailing charge that would
be allowed for the same service performed by a
physician, or, for services furnished on or after
January 1, 1992, 65 percent (or 100 percent for
services furnished on or after January 1, 2011) of the
fee schedule amount provided under section 1848 for the
same service performed by a physician), (L) with
respect to qualified psychologist services under
section 1861(s)(2)(M), the amounts paid shall be 80
percent of the lesser of the actual charge for the
services or the amount determined by a fee schedule
established by the Secretary for the purposes of this
subparagraph, (M) with respect to prosthetic devices
and orthotics and prosthetics (as defined in section
1834(h)(4)), the amounts paid shall be the amounts
described in section 1834(h)(1), (N) with respect to
expenses incurred for physicians' services (as defined
in section 1848(j)(3)) other than personalized
prevention plan services (as defined in section
1861(hhh)(1)), the amounts paid shall be 80 percent of
the payment basis determined under section 1848(a)(1),
(O) with respect to services described in section
1861(s)(2)(K) (relating to services furnished by
physician assistants, nurse practitioners, or clinic
nurse specialists), the amounts paid shall be equal to
80 percent of (i) the lesser of the actual charge or 85
percent of the fee schedule amount provided under
section 1848, or (ii) in the case of services as an
assistant at surgery, the lesser of the actual charge
or 85 percent of the amount that would otherwise be
recognized if performed by a physician who is serving
as an assistant at surgery, (P) with respect to
surgical dressings, the amounts paid shall be the
amounts determined under section 1834(i), (Q) with
respect to items or services for which fee schedules
are established pursuant to section 1842(s), the
amounts paid shall be 80 percent of the lesser of the
actual charge or the fee schedule established in such
section, (R) with respect to ambulance services, (i)
the amounts paid shall be 80 percent of the lesser of
the actual charge for the services or the amount
determined by a fee schedule established by the
Secretary under section 1834(l) and (ii) with respect
to ambulance services described in section 1834(l)(8),
the amounts paid shall be the amounts determined under
section 1834(g) for outpatient critical access hospital
services, (S)(i) except as provided in clause
(ii),subject to subparagraph (EE), with respect todrugs
and biologicals (including intravenous immune globulin
(as defined in section 1861(zz))) not paid on a cost or
prospective payment basis as otherwise provided in this
part (other than items and services described in
subparagraph (B)), the amounts paid shall be 80 percent
of the lesser of the actual charge or the payment
amount established in section 1842(o) (or, if
applicable, under section 1847, 1847A, or 1847B),
and(ii) with respect to insulin furnished on or after
July 1, 2023, through an item of durable medical
equipment covered under section 1861(n), the amounts
paid shall be, subject to the fourth sentence of this
subsection, 80 percent of the payment amount
established under section 1847A (or section 1847B, if
applicable) for such insulin, (T) with respect to
medical nutrition therapy services (as defined in
section 1861(vv)), the amount paid shall be 80 percent
(or 100 percent if such services are recommended with a
grade of A or B by the United States Preventive
Services Task Force for any indication or population
and are appropriate for the individual) of the lesser
of the actual charge for the
Additional Views
My colleagues, cancer affects everyone. Today's mark-up
represents a result of dedicated work towards one common goal:
providing a coverage pathway for innovative cancer screenings.
This mark-up is of the utmost importance given the impact
cancer continues to have upon our closest colleagues. A late-
stage cancer diagnosis stole our nation's champion and our
dear, John Lewis. Cancer diagnosed in late stage stole Speaker
Mike Johnson's 63-year-old father from him just 3 days before
he was sworn in. Last Congress, our colleague, Sheila Jackson
Lee shared her diagnosis of pancreatic cancer. This Congress,
we have already lost three colleagues, Congressmen Slyvester
Turner, Raul Grijalva, and Gerald Connolly to the battle of
cancer. Cancer, indeed, knows no bounds. It can and does affect
everyone.
This fight against cancer is personal to me, a late-stage
cancer diagnosis took the life of my mother--the namesake for
this important legislation, Ms. Nancy Gardner Sewell. I want to
thank our colleague Rep. Jodie Arrington for being a co-
champion of this bill and for surprising and honoring me in
naming the bill after my mother, Nancy Gardner Sewell.
Who was she? My mom was:
A devout Christian who lived a life of
faith.
An exemplary educator and librarian-media
specialist. She served in the Selma schools for 36
years, where she shaped minds and lifted up children.
As a librarian, she was a strong advocate of reading
and a champion of literacy initiating the Reading is
Fundamental (RIF) program in 1973 delivering books to
children throughout Alabama, Mississippi and Tennessee.
A program that still serves the kids in Selma-Dallas
County and Alabama's rural blackbelt.
Nancy Sewell was a trailblazing civic
leader. She became the first African American woman
elected to Selma's City Council and served as an
inspirational role model for women in politics.
Her favorite saying was ``Bloom where you are planted''.
You can make a difference right where you are. And she made a
big difference in the lives of the many people she touched. My
mother believed in community. She believed that knowledge
mattered. She believed that no one should be left behind--she
strove to build bridges and tear down walls of injustice. Her
life's work was about service, about caring, about making sure
people had what they needed to flourish.
My Mom represents one of the millions of people who have
lost their battle to cancer, and my personal story represents
one of the millions of loved ones who have had to endure such a
horrible loss. It is our duty to do whatever we can to rid this
nation of the scourge of cancer by giving coverage and access
to the most vulnerable in our society. Therefore, I hope you
will join me in supporting H.R. 842 the Nancy Gardner Sewell
Medicare Multi-Cancer Early Detection Screening Coverage Act.
Currently, this bill has overwhelming bipartisan support in
both chambers of Congress! 295 of our colleagues in the House
of Representatives, and 62 in the Senate have signed on to
cosponsor this legislation since its introduction in February!
I am also overwhelmed by the support this bill has earned
from cancer advocacy groups-- such as the American Cancer
Society Cancer Action Network, the Prevent Cancer Foundation,
the National Minority Quality Forum, The Association of
Community Cancer Centers, Cancer Support Community, Fight
Colorectal Cancer, Go2 for Lung Cancer, The National Grange,
the Ovarian Cancer Research Alliance, and more than 600
advocacy organizations across the country which include more
than a dozen organizations in my home state of Alabama!
Mr. Chairman, I would like to acknowledge and thank the
patient advocates attending today's markup. I request unanimous
consent to enter the 2025 letter of support from the Prevent
Cancer Foundation listing every nationwide endorsing
organizations of this legislation.
Like so many Americans, my mother received her diagnosis of
pancreatic cancer after the cancer had already spread, making
it harder to treat. New cancer screening tools have the
potential to change this. Multi-cancer early detection tests
can screen for dozens of cancers--such as pancreatic--for which
we have not previously been able to screen. This means we can
catch more cancers in their earlier stages, giving patients
their best chance at beating the disease.
This year, more than 600,000 Americans will die from
cancer. This number could easily be reduced with early
detection tools! 66 is the median age for receiving a cancer
diagnosis in the United States. This legislation serves to
provide our seniors the opportunity to fight cancer earlier
when it is less deadly. When there are steps we can take to
reduce the suffering associated with cancer, it is our
responsibility to do so.
For Congress today this means ensuring Americans have
access to the most effective tools to help combat the disease.
Medicare laws do not currently provide timely coverage of these
technologies. It is our job to proactively ensure accessibility
for those who need it most.
We must step in and create a pathway for coverage and
access for early detection tests. That is exactly what the MCED
bill does. Like similar legislation we have passed that create
coverage pathways and access for mammography and colorectal
screenings. This legislation will drive value in Medicare by
reducing the significant costs attributed to advanced cancer
care, and more importantly, it will save lives.
I am so thankful for the support this bill has received,
both in Congress and amongst the cancer community. This bill
passed unanimously out of this committee last Congress, and I
pray we do so again today!
Our work is not done until this bill becomes law. Millions
of Americans are counting on us.
Thank you.
Terri A. Sewell.
SUPPLEMENTAL VIEWS
H.R. 842 adds multi-cancer early detection (MCED) screening
tests as a covered benefit under Medicare, effective January 1,
2029. MCED tests have the potential to concurrently detect
multiple cancer types across multiple organ sites. The
legislation requires that an MCED test must be cleared under
section 510(k), classified under section 513(f)(2), or approved
under section 515 of the Federal Food, Drug, and Cosmetic Act
(FD&C Act) for Medicare coverage.
Under the Amendment in the Nature of a Substitute (ANS)
reported out, Medicare can only pay for one test per year for
an individual over 50 years of age and under 65 in 2029 (under
65 of age increases by one year for each succeeding year of
coverage, so under 66 in 2030 and so on). Despite this
inequitable approach, the bill importantly allows the Secretary
to ensure coverage is tailored to patient needs once the
clinical evidence is available. Once the tests are recommended
by a grade of A or B by the United States Preventive Services
Task Force (USPSTF), they will be covered as a preventive
service through Medicare's traditional preventive services
coverage pathway, and the bill's prescribed age and frequency
limitations would not apply but would instead follow the USPSTF
recommendations.
The original bill did not limit access to MCED screenings
on the basis of age. While Democrats strongly support ensuring
access to cancer screenings and unanimously supported the
legislation in Committee, it is preferable to not base the
determination of access to these MCED screening on an arbitrary
age.
Meanwhile, Republicans have actively tried to restrict
access to needed, evidence-based care, while decimating the
very research infrastructure necessary to bring new scientific
innovations to market. Over the last nine months, the Trump
Administration has slashed nationwide National Institutes of
Health (NIH) funding, terminating hundreds of scientific
grants. This rapid disinvestment in scientific research
endangers patient care, jobs and the economy and threatens
America's world leadership in health care innovation and cures.
CBO recently reported that cuts to the Food and Drug
Administration FDA and National Institutes of Health (NIH) will
hinder the development of new drugs.\1\ Specifically, cuts
resulting in a nine-month increase in FDA review times cuts to
preclinical NIH funding will result in 53 fewer newer
prescription drugs over the next three decades.
---------------------------------------------------------------------------
\1\https://www.cbo.gov/system/files/2025-07/61373-Drugs.pdf.
---------------------------------------------------------------------------
The world's largest public funder of biomedical research,
the
NIH drives discoveries that lead to life-saving therapies and
generates economic growth. NIH funding spurred an estimated
$92.89 billion in economic activity in Fiscal Year (FY) 2023
alone. For every $100 million of funding, NIH-supported
research generates 76 patents, which create opportunities for
an estimated $598 million in further research and
development.\2\ In FY 2023 alone, NIH awarded $37.81 billion in
research funding across all 50 states and Washington, D.C.,
supporting 412,041 jobs.\3\
---------------------------------------------------------------------------
\2\https://www.nih.gov/about-nih/what-we-do/impact-nih-research/
serving-society/direct-econom ic-contributions.
\3\https://www.unitedformedicalresearch.org/wp-content/uploads/
2024/03/UMR-NIHs-Role-in-Sustaining-the-US-Economy-2024-Update.pdf.
The Trump Administration has terminated hundreds--possibly
thousands--of NIH grants for scientific research.\4\ These
cuts threaten U.S. leadership in medical research, allowing
countries like China to expand their investments in biomedical
re-
search and surpass the U.S. in developing future treatments and
cures.\5\ Leading specialty medical societies have raised the
alarm bells:
---------------------------------------------------------------------------
\4\https://taggs.hhs.gov/Content/Data/HHS_Grants_Terminated.pdf.
\5\Government of China, (2022), 14th Five-Year Plan for Bioeconomy
Development, https://leap.unep.org/en/countries/cn/national-
legislation/14th-five-year-plan-bioeconomy-development.
The very research that drives medical advancements,
fuels economic growth, and sustains America's
competitive edge will suffer--not because of a lack of
talent or opportunity but because of an arbitrary
policy that undermines the financial sustainability of
research institutions . . . This policy shift would
undermine America's biomedical leadership, erode its
workforce competitiveness, and threaten national
security, ultimately ceding scientific and
technological dominance to global competitors.\6\
---------------------------------------------------------------------------
\6\https://www.aans.org/wp-content/uploads/2025/03/Physician-
Response-to-NIH-Indirect-Cost-Policy-2025-03-05-final.pdf.
Trump Administration policies are threatening clinical
trials that patients and families depend on to access to
therapies, including cancer prevention and treatment.
Researchers may be forced to halt clinical trials abruptly,
leaving patients and physicians without other options.\7\ A
letter from thousands of patients with rare diseases notes:
---------------------------------------------------------------------------
\7\https://www.theatlantic.com/health/archive/2025/03/trump-nih-
clinical-trials-patient-safey/682217/.
--The removal of key experts at Health and Human
Services Agencies, including NIH, FDA [Food and Drug
Administration], and CDC [Centers for Disease Control
and Prevention]--paired with recent executive orders on
federal funding and communications, compromises our
nation's economic prosperity and threatens the
foundation that enables hope. For children and adults
with rare diseases, even a momentary pause in funding
for these programs and agencies will have devastating,
life-altering consequences.\8\
---------------------------------------------------------------------------
\8\https://everylifefoundation.quorum.us/campaign/111750/.
Furthermore, cutting funding to U.S research institutions
and medical centers will deprive all families of new treatments
and medical breakthroughs. Attorneys General from 22 states
sued the Trump Administration, the Department of Health and
Human Services (HHS), and the NIH for unlawfully cutting funds
that support cutting-edge medical and public health research at
universities and research institutions across the country.\9\
---------------------------------------------------------------------------
\9\https://www.mass.gov/news/ag-campbell-sues-trump-administration-
for-defunding-medical-and-public-health-innovation-research.
The war on ``Diversity, Equity, and Inclusion'' harms
product development and scientific knowledge. In March, in an
unprecedented move, the NIH abruptly terminated millions of
dollars of research awards to scientists related to diversity,
equity, and inclusion, in violation of court orders from
federal judges, effectively imposing conditions on funding that
did not exist at the time the grants were awarded.\10\
---------------------------------------------------------------------------
\10\https://www.bostonglobe.com/2025/03/06/metro/trump-kills-
science-funding-dei/.
By terminating programs that ensure robust participation in
clinical trials, the Trump Administration is attempting to
illegally block companies from complying with clinical trial
requirements set by Congress to ensure new therapies have
complete information on how they work for all Americans when
they come to market. Congress requires drug and device
companies to develop diversity plans, which will ultimately
enable them to enroll more diverse patient populations in
clinical trials and ensure representation of populations, who
will use the medical products once approved.\11\ Diverse
representation in clinical trials is a scientific necessity.
For example, cancer research has shown that the effectiveness
of certain treatments can vary based on genetic or ethnic
backgrounds, making diverse enrollment critical.\12\
---------------------------------------------------------------------------
\11\https://www.fda.gov/regulatory-information/selected-amendments-
fdc-act/food-and-drug-
omnibus-reform-act-fdora-2022.
\12\https://www.cancer.gov/research/infrastructure/clinical-trials/
nci-supported/nci-match::text=
NCI%2DMATCH%2C%20also%20known%20as,no%20matter%20the%20cancer%20type.
Rolling back programs that ensure clinical trials and other
research are representative of the U.S. at large will not only
make it harder to recruit a broad array of study participants--
which is a setback for science--but it will also reverse
---------------------------------------------------------------------------
decades of progress in reducing disparities in health outcomes.
The unprecedented levels of HHS cuts will hinder
development, approval, and access to drugs, including
biosimilars, potentially increasing risk to patient health and
safety. This administration indiscriminately and almost
immediately fired thousands of federal workers, including those
that oversee medical device safety, food safety, and clinical
trials, which will slow innovation and affect the safety and
availability of consumer products--including food, drugs, and
devices--as well as responses to public health threats, such as
influenza, measles, and other infectious disease
outbreaks.\13\\14\\15\ Specifically:
---------------------------------------------------------------------------
\13\https://abcnews.go.com/US/agencies-federal-workers-fired/
story?id=118901289.
\14\https://www.nytimes.com/2025/02/18/us/politics/fda-cdc-health-
department-trump.html.
\15\https://www.msn.com/en-us/health/other/cdc-invites-back-about-
180-fired-employees-includ ing-some-who-help-fight-outbreaks/ar-
AA1Ak2VV?ocid=BingNewsSerp.
Sweeping cuts at the NIH will hinder the
world's largest funder of biomedical research in the
nation's development of new drugs. These cuts currently
stand at six percent of NIH's workforce and include the
parts of NIH responsible for decisions regarding what
diseases to study and medicines to develop.\16\
---------------------------------------------------------------------------
\16\Megan Molteni, et al., Five NIH Institute Directors and
Numerous Lab Heads Ousted in Unprecedented Shake-Up, STAT (April 1,
2025), https://www.statnews.com/2025/04/01/nih-rif-1200-layoffs-raise-
concerns-health-medicine-biomedical-research/ (last visited April 2,
2025).
Drastic cuts totaling 19 percent of the Food
and Drug
Administration (FDA) budget will compromise the
agency's
ability to approve new biosimilars and ensure their
safety.
This rollback will erode the agency's core functions,
including
monitoring drug safety, and evaluating and approving
new drugs, devices, and vaccines.\17\ Without qualified
staff to review drug applications and inspect new
manufacturing facilities, patients cannot safely access
these drugs.
---------------------------------------------------------------------------
\17\Lizzy Lawrence and Sarah Todd, FDA Commissioner Marty Makary
Gets Off to a Brusing Start as Agency Is Wracked by Layoffs, STAT
(April 1, 2025), https://www.statnews.com/2025/04/01/fda-rif-3500-
layoff-notices-under-rfk-jr-hhs-reorganization/ (last visited April 2,
2025).
Staffing cuts at the CDC will affect the
monitoring of emerging disease and public health
threats.
Republicans have put their extremist views ahead of finding
a cure for cancer. President Biden's Cancer Moonshot initiative
sought to accelerate development of cures for cancer. It was
the largest organized effort ever by the federal government to
accelerate cancer research, find cures, and reduce cancer
deaths by half within 30 years--and the nearly $2 billion
investment received bipartisan support and praise. The program
was funded on a bipartisan basis in the 21st Century Cures
Act.\18\ Unfortunately, Republicans zeroed out funding for the
Cancer Moonshot in March of 2024.\19\
---------------------------------------------------------------------------
\18\https://www.congress.gov/bill/114th-congress/house-bill/34.
\19\https://www.politico.com/news/2024/04/29/congress-is-killing-
bidens-cancer-moonshot-00154718.
Currently, the FDA has cleared, classified, or approved no
MCED tests, and research is ongoing to understand the benefits
of using MCED tests in routine clinical practice. MCED tests
aim to detect many types of cancer early using noninvasive
methods like blood tests, which could lead to earlier
treatment. However, early detection does not always improve the
chance of a cure or extend life for some cancers.\20\ Follow-up
tests are needed to confirm a diagnosis, and research has shown
that more than half the time, no cancer could be found in
people who had a positive MCED test.\21\ Clinical trial data
will be critical to determine whether detection with MCED tests
improves outcomes such as cancer-related survival.\22\\23\\24\
This